A Phase 1 Open-Label Study in Healthy Adult Subjects to Assess the Effect of Cenicriviroc Mesylate (CVC) on the Pharmacokinetics (PK) of HMG-CoA Reductase Inhibitors (Rosuvastatin, Atorvastatin and Simvastatin), Caffeine and Digoxin

Trial Profile

A Phase 1 Open-Label Study in Healthy Adult Subjects to Assess the Effect of Cenicriviroc Mesylate (CVC) on the Pharmacokinetics (PK) of HMG-CoA Reductase Inhibitors (Rosuvastatin, Atorvastatin and Simvastatin), Caffeine and Digoxin

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Cenicriviroc (Primary) ; Atorvastatin; Caffeine; Digoxin; Rosuvastatin; Simvastatin
  • Indications Cancer; Diabetic nephropathies; Graft-versus-host disease; HIV-1 infections; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
  • Focus Pharmacokinetics
  • Sponsors Tobira Therapeutics
  • Most Recent Events

    • 21 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 03 Oct 2016 According to Tobira Pharmaceuticals media release, data will be presented at data presentations at the American Academy for the Study of Liver Diseases (AASLD) Annual Meeting 2016.
    • 23 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top